|
[1] RAJESH S,MUKUND A,SUREKA B,et al. Non-cirrhotic portal hypertension:An imaging review[J]. Abdom Radiol(NY),2018,43(8):1991-2010.
|
|
[2] CUNNINGHAM ME,PARASTANDEH-CHEHR G,CEROCCHI O,et al. Noninvasive predictors of high-risk varices in patients with non-cirrhotic portal hypertension[J]. Can J Gastroenterol Hepatol,2019,2019:1808797.
|
|
[3] ZHANG BJ,HAN GH,FAN DM. Research advances in noncirrhotic portal hypertension[J]. J Clin Hepatol,2016,32(2):245-249.(in Chinese)张博静，韩国宏，樊代明．非肝硬化性门静脉高压症的研究现状[J]．临床肝胆病杂志，2016,32(2):245-249.
|
|
[4] PARGEWAR SS,DESAI SN,RAJESH S,et al. Imaging and radiological interventions in extra-hepatic portal vein obstruction[J]. World J Radiol,2016,8(6):556-570.
|
|
[5] KHANNA R,SARIN SK. Idiopathic portal hypertension and extrahepatic portal venous obstruction[J]. Hepatol Int,2018,12(Suppl 1):148-167.
|
|
[6] SARIN SK,SOLLANO JD,CHAWLA YK,et al. Consensus on extra-hepatic portal vein obstruction[J]. Liver Int,2006,26(5):512-519.
|
|
[7] JABEEN S,ROBBANI I,CHOH NA,et al. Spectrum of biliary abnormalities in portal cavernoma cholangiopathy(PCC)secondary to idiopathic extrahepatic portal vein obstruction(EHPVO)-a prospective magnetic resonance cholangiopancreaticography(MRCP)based study[J]. Br J Radiol,2016,89(1068):20160636.
|
|
[8] de FRANCHIS R,Baveno VI Faculty. Expanding consensus in portal hypertension:Report of the Baveno VI Consensus Workshop:Stratifying risk and individualizing care for portal hypertension[J]. J Hepatol,2015,63(3):743-752.
|
|
[9] TEFFERI A. Primary myelofibrosis:2019 update on diagnosis,risk-stratification and management[J]. Am J Hematol,2018,93(12):1551-1560.
|
|
[10] ALVAREZ-LARRAN A,ABRALDES JG,CERVANTES F,et al. Portal hypertension secondary to myelofibrosis:A study of three cases[J]. Am J Gastroenterol,2005,100(10):2355-2358.
|
|
[11] ABU-HILAL M,TAWAKER J. Portal hypertension secondary to myelofibrosis with myeloid metaplasia:A study of 13 cases[J]. World J Gastroenterol,2009,15(25):3128-3133.
|
|
[12] SONG ZQ,ZHOU LY. A clinical analysis of six cases of portal hypertension secondary to primary myelofibrosis and review of literatures[J]. Chin J Intern Med,2010,49(10):845-847.(in Chinese)宋志强，周丽雅．原发性骨髓纤维化继发门脉高压症六例分析并文献复习[J]．中华内科杂志，2010,49(10):845-847.
|
|
[13] RIGGIO O,GIOIA S,PENTASSUGLIO I,et al. Idiopathic noncirrhotic portal hypertension:Current perspectives[J]. Hepat Med,2016,8:81-88.
|
|
[14] FIEL MI,SCHIANO TD. Idiopathic noncirrhotic portal hypertension[J]. Semin Diagn Pathol,2019,36(6):395-403.
|
|
[15] SCHOUTEN JN,GARCIA-PAGAN JC,VALLA DC,et al. Idiopathic noncirrhotic portal hypertension[J]. Hepatology,2011,54(3):1071-1081.
|
|
[16] BAO WC,QI XS,TANG SH,et al. An excerpt of the Japanese research group on IPH:Diagnosis and treatment guidelines for aberrant portal hemodynamics(2017)[J]. J Clin Hepatol,2017,33(3):432-434.(in Chinese)暴文春，祁兴顺，汤善宏，等．《2017年日本特发性门静脉高压研究组:门静脉血流动力学异常相关疾病诊治指南》摘译[J]．临床肝胆病杂志，2017,33(3):432-434.
|
|
[17] LI Y,ZHOU XG,YANG K,et al. Analysis of pathological features of 42 cases with idiopathic non-cirrhotic portal hypertension[J]. Chin J Dr,2020,48(3):291-294.(in Chinese)李越，周新刚，杨坤，等．42例特发性非肝硬化性门脉高压的病理特点分析[J]．中国临床医生杂志，2020,48(3):291-294.
|
|
[18] KHANNA R,SARIN SK. Non-cirrhotic portal hypertensiondiagnosis and management[J]. J Hepatol,2014,60(2):421-441.
|
|
[19] XU HF,DING HG. Diagnosis and treatment of pre-hepatic(sinusoidal)non-cirrhotic portal hypertension and related difficulties[J]. J Clin Hepatol,2019,35(1):13-17.(in Chinese)徐航飞，丁惠国．肝(窦)前型非肝硬化门静脉高压症的诊断与治疗及其面临的困境[J]．临床肝胆病杂志，2019,35(1):13-17.
|
|
[20] de GOTTARDI A,RAUTOU PE,SCHOUTEN J,et al. Porto-sinusoidal vascular disease:Proposal and description of a novel entity[J]. Lancet Gastroenterol Hepatol,2019,4(5):399-411.
|
|
[21] ZHU B,DU Z,WANG Z,et al. Congenital hepatic fibrosis in children and adults:Clinical manifestations, management,and outcome-case series and literature review[J]. Gastroenterol Res Pract,2020,2020:8284274.
|
|
[22] LOCATELLI L,CADAMURO M,SPIRLìC,et al. Macrophage recruitment by fibrocystin-defective biliary epithelial cells promotes portal fibrosis in congenital hepatic fibrosis[J]. Hepatology,2016,63(3):965-982.
|
|
[23] PARKASH A,CHEEMA HA,MALIK HS,et al. Congenital hepatic fibrosis:Clinical presentation,laboratory features and management at a tertiary care hospital of Lahore[J]. J Pak Med Assoc,2016,66(8):984-988.
|
|
[24] KRITHARIS A,AL-SAMKARI H,KUTER DJ. Hereditary hemorrhagic telangiectasia:Diagnosis and management from the hematologist’s perspective[J]. Haematologica,2018,103(9):1433-1443.
|
|
[25] ELISABETTA B,SILVIA G,SAVERIO A,et al. Liver involvement in hereditary hemorrhagic telangiectasia[J]. Abdom Radiol,2018,43(8):1920-1930.
|
|
[26] RUAN ZB,JIAO J,MIN DY,et al. Clinical and imaging features of hepatic hereditary hemorrhagic telangiectasia[J]. J Clin Radiol,2018,37(8):1314-1319.(in Chinese)阮志兵，焦俊，闵定玉，等．肝脏遗传性出血性毛细血管扩张症的CT表现特点及漏诊、误诊分析[J]．临床放射学杂志，2018,37(8):1314-1319.
|
|
[27] ZHAO JQ,HUO F,WANG SP,et al. Liver transplantation treats hepatic hereditary hemorrhagic telangiectasia:A case report[J].Chin J Organ Transplant,2017,38(3):184-187.(in Chinese)赵纪强，霍枫，汪邵平，等．肝移植治疗肝脏遗传性毛细血管扩张症一例[J]．中华器官移植杂志2017,38(3):184-187.
|
|
[28] Cooperative Group for Hepatic and Gal Diseases,Chinese Society of Gastroenterology,Chinese Medical Association. Expert consensus on diagnosis and treatment of quinazoline alkaloidsrelated sinusoidal obstruction syndrome(2017,Nanjing)[J]. J Clin Hepatol,2017,33(9):1627-1637.(in Chinese)中华医学会消化病学分会肝胆疾病协作组．吡咯生物碱相关肝窦阻塞综合征诊断和治疗专家共识意见(2017年，南京)[J]．临床肝胆病杂志，2017,33(9):1627-1637.
|
|
[29] YANG XQ,YE J,LI X,et al. Pyrrolizidine alkaloids-induced hepatic sinusoidal obstruction syndrome:Pathogenesis,clinical manifestations,diagnosis,treatment,and outcomes[J].World J Gastroenterol,2019,25(28):3753-3763.
|
|
[30] NASSEREDDINE S,ALSUBAIT S,TABBARA I. Sinusoidal obstruction syndrome(veno-occlusive disease)following hematopoietic stem cell transplant:Insights and therapeutic advances[J]. Anticancer Res,2018,38(5):2597-2605.
|
|
[31] European Association for the Study of the Liver. EASL clinical practice guidelines:Vascular diseases of the liver[J]. J Hepatol,2016,64(1):179-202.
|
|
[32] LIU ZL,FAN ZP,GOU YS,et al. Clinical features,pathogenesis,and diagnosis and treatment of different types of hepatic sinusoidal obstruction syndrome[J]. J Clin Hepatol,2019,35(1):208-212.(in Chinese)刘贞利，范作鹏，勾钰淞，等．不同类型肝窦阻塞综合征的临床特征、发病机制与诊治[J]．临床肝胆病杂志，2019,35(1):208-212.
|
|
[33] DAS CJ,SONEJA M,TAYAL S,et al. Role of radiological imaging and interventions in management of Budd-Chiari syndrome[J]. Clin Radiol,2018,73(7):610-624.
|
|
[34] DANG XW,LI LH,LI L,et al. Application value of clinical typing in the treatment of Budd-Chiari syndrome[J]. Chin J Dig Surg,2016,15(7):696-701.(in Chinese)党晓卫，李路豪，李林，等．布加综合征临床分型在其治疗中的应用价值[J]．中华消化外科杂志，2016,15(7):696-701.
|
|
[35] KHAN F,ARMSTRONG MJ,MEHRZAD H,et al. Review article:A multidisciplinary approach to the diagnosis and management of Budd-Chiari syndrome[J]. Aliment Pharmacol Ther,2019,49(7):840-863.
|
|
[36] LIU L,QI XS,ZHAO Y,et al. Budd-Chiari syndrome:Current perspectives and controversies[J]. Eur Rev Med Pharmacol Sci,2016,20(15):3273-3281.
|
|
[37] GOEL RM,JOHNSTON EL,PATEL KV,et al. Budd-Chiari syndrome:Investigation,treatment and outcomes[J]. Postgrad Med J,2015,91(1082):692-697.
|
|
[38] VALLA DC. Budd-Chiari syndrome/hepatic venous outflow tract obstruction[J]. Hepatol Int,2018,12(Suppl 1):168-180.
|
|
[39] GRUS T,LAMBERT L,GRUSOVG,et al. Budd-Chiari syndrome[J]. Prague Med Rep,2017,118(2-3):69-80.
|
|
[40] HU Q,XIANG CH. Current status regarding diagnosis and management of idiopathic portal hypertension[J]. Chin J Gen Surg,2016,8(1):117-124.(in Chinese)朱青，项灿宏．特发性门静脉高压症的诊治现状[J]．中国普通外科杂志，2019,28(1):117-124.
|
DownLoad: